Evidence Table J3: DISCRETE outcomes for class ANTI-BACTERIAL (ORAL)/RETINOID (TOPICAL)

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	J.01.02			**Vitamin A + oxytetracycline**	**Vehicle + oxytetracycline**	
57 ↑ Parallel N=238		**Side effects**		Erythema alone 11 Desquamation alone 3 Erythema + desquamation 52 Itching or pain 4	Erythema alone 10 Desquamation alone 6 Erythema + desquamation 7 Itching or pain 2	**NS**
				Vomiting or nausea 0 Diarrhea 0 fatigue 0	Vomiting or nausea 2 Diarrhea 0 Fatigue 0	
		Side effects		Any side effects 66 No side effects 13	Any side effects 25 No side effects 54	**NS**
		Comedones change	Mid (8)	Worse 2 No change 2 0-49% reduction 11 50-74% reduction 20	Worse 6 No change 16 0-49% reduction 19 50-74% reduction 25	**NS**
				75-100%, reduction 65	75-100%, reduction 34	
		Papules change	Mid (8)	Worse 5 No change 9 0-49% reduction 13 50-74% reduction 25	Worse 8 No change 8 0--49% reduction 21 50-74% reduction 32	**NS**
				75-100%, reduction 48	75-100%, reduction 31	
		Pustules change	Mid (8)	Worse 2 No change 11 0-49% reduction 50-74% reduction 13	Worse 2 No change 5 0-49% reduction 9 50-74% reduction 24	**NS**
				75-100%, reduction 74	75-100%, reduction 60	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.